Early Treatment Response Predicts Outcome in Paediatric Ulcerative Colitis: Gastroenterology: Inflammatory Bowel Disease
| Autor: | Marco Gasparetto, Franco Torrente, G. Noble-Jamieson, Vivien Wong-Spracklen, M. Brennan, Kate J. Howell, Robert Heuschkel, Matthias Zilbauer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Pancolitis Adolescent Sensitivity and Specificity Severity of Illness Index Inflammatory bowel disease Medical Records 03 medical and health sciences 0302 clinical medicine Gastrointestinal Agents Internal medicine Severity of illness medicine Humans Prospective Studies Colitis Child Prospective cohort study business.industry Medical record Remission Induction Gastroenterology Prognosis medicine.disease Ulcerative colitis Infliximab Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health Cohort Colitis Ulcerative Female 030211 gastroenterology & hepatology medicine.symptom business |
| Zdroj: | Journal of Pediatric Gastroenterology & Nutrition. 67:217-220 |
| ISSN: | 1536-4801 0277-2116 |
| DOI: | 10.1097/mpg.0000000000001941 |
| Popis: | The disease course of children with ulcerative colitis (UC) varies substantially. Published data on predictors of disease outcomes in children remain scarce. We validate clinical predictors of outcomes in 93 children with UC in a single centre (age range: 2-18 years, minimum follow-up: 18 months). We stratified children into 3 groups according to their disease course, that is, 1 = mild (38/93, 40.9%), 2 = moderate (38/93, 40.9%), 3 = severe (17, 18.2%). Comparison of clinical and biochemical parameters was performed between groups using Chi-square, Mann-Whitney, and log-rank tests. Predictors of a severe disease course included pancolitis (P 0.01), low albumin (P 0.005), low haemoglobin at diagnosis (P 0.04), paediatric ulcerative colitis activity index (PUCAI) at 3 months, and nonresponse to steroids at 3 months (P 0.0001). In our cohort, failure to achieve remission at 3 months implied an 80% likelihood to require biologics or major surgery within 18 months. A specific 3-month review point is recommended to guide future management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text